Genomic Testing


UroSeq® Hereditary DNA Repair Gene Panel measures the expression of certain genes in your prostate cancer cells. That information allows for development of a personalized treatment plan for patients. It may also indicate that family members are at increased risk of prostate or other types of cancer. Genomic testing is performed on the patient’s germline DNA (the DNA with which you were born). Strand’s UroSeq Hereditary DNA Repair Gene Panel incorporates sequencing of particular DNA segment to examine the order of DNA nucleotides, or bases, to determine if any mutations are present.

Strand uses buccal swabs already collected with the know error® system to obtain germline DNA samples sufficient to run its UroSeq® Hereditary DNA Repair Gene Panel test. Strand’s laboratory uses next generation sequencers to sequence the patient’s germline DNA sample. Strand’s bioinformatics are used to identify and report any mutations. Inherited genetic mutations can increase a person’s risk of developing cancer through a variety of mechanisms depending on the function of the gene. Mutations in genes that control cell growth and the repair of damaged DNA are likely to be associated with increased cancer risk.

Data published in The New England Journal of Medicine indicate that as many as 1 in 10 prostate cancer patients may have a repair gene mutation. Changes to those genes provide critical information that may indicate a more aggressive cancer, increased sensitivity to certain therapies or an increased risk of additional cancers. 



Pritchard, C.C, et al. (2016). The New England Journal of Medicine. 375; 5, 443-453.